Compare TCBX & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBX | KMDA |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 385.3M |
| IPO Year | 2021 | N/A |
| Metric | TCBX | KMDA |
|---|---|---|
| Price | $39.89 | $7.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $41.67 | $13.00 |
| AVG Volume (30 Days) | 67.5K | ★ 103.4K |
| Earning Date | 01-21-2026 | 11-10-2025 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | ★ 38.90 | 30.41 |
| EPS | ★ 3.56 | 0.35 |
| Revenue | ★ $192,224,000.00 | $174,787,000.00 |
| Revenue This Year | $24.66 | $14.79 |
| Revenue Next Year | $17.56 | $10.74 |
| P/E Ratio | ★ $11.10 | $19.97 |
| Revenue Growth | ★ 20.96 | 10.36 |
| 52 Week Low | $25.17 | $5.54 |
| 52 Week High | $41.70 | $9.16 |
| Indicator | TCBX | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 52.82 |
| Support Level | $39.28 | $6.97 |
| Resistance Level | $41.70 | $7.45 |
| Average True Range (ATR) | 1.08 | 0.17 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 51.08 | 56.24 |
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.